Dharam Paul

USPTO Granted Patents = 19 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 7.1

ph-index = 3

Forward Citations = 17(Granted Patents)

Location History:

Bellfield, AU (2012 - 2013)
Torrensville, AU (2012 - 2013)
Thebarton, AU (2017 - 2018)
Flinders Park, AU (2015 - 2019)

Company Filing History:

Merck Sharp + Dohme Corp.

Ironwood Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12409140 - Therapeutic formulations and uses thereof (2025-09-09),

2. 12331022 - Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors (2025-06-17),

3. 12139473 - Substituted-N-heteroaryl compounds and uses thereof (2024-11-12),

4. 12090146 - Substituted-pyridinyl compounds and uses thereof (2024-09-17),

5. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),

6. 9994518 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof (2018-06-12),

7. 9914702 - Amine derivatives as potassium channel blockers (2018-03-13),

8. 9790173 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I (2017-10-17),

9. 9758516 - Crystalline form of an anxiolytic compound (2017-09-12),

10. 9745296 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2017-08-29),

11. 9493451 - Amine derivatives as potassium channel blockers (2016-11-15),

12. 9133188 - Methods for preparing naphthyridines (2015-09-15),

13. 9062013 - Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof (2015-06-23),

14. 9023848 - Small-molecules as therapeutics (2015-05-05),

15. 8507539 - Potassium channel blockers and uses thereof (2013-08-13),

Title: **Innovative Contributions of Dharam Paul in Neuroscience**

Introduction

Dharam Paul, an innovative inventor based in Flinders Park, Australia, has made significant contributions to the field of neuroscience through his extensive research and development of new compounds. With a total of 18 patents to his name, Paul is dedicated to addressing various central nervous system disorders through groundbreaking inventions.

Latest Patents

Among Dharam Paul's latest patents is the one for "Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors." This patent focuses on compounds that modulate the α7 nicotinic acetylcholine receptor, offering potential interventions for cognitive impairments related to diseases such as Alzheimer's, Parkinson’s, and schizophrenia. Additionally, another of his recent patents titled "Substituted-N-heteroaryl compounds and uses thereof" presents activators of Kv3.1 and Kv3.2 channels. These activators hold therapeutic promise for treating cognitive dysfunction and negative symptoms associated with various central nervous system disorders, including Tourette's syndrome, autism, and epilepsy.

Career Highlights

Dharam Paul's career is marked by significant achievements in the pharmaceutical and biotechnology sectors. He has collaborated with notable organizations, including Bionomics Inc. and Merck Sharp & Dohme Corporation. His work has been crucial in the discovery and development of new therapeutic solutions for complex neurological conditions.

Collaborations

Throughout his career, Dharam Paul has worked alongside esteemed professionals such as Andrew John Harvey and Bernard Luke Flynn. These collaborations have undoubtedly enriched his research and contributed to the successful development of his novel compounds.

Conclusion

Dharam Paul's commitment to innovation in the field of neuroscience is evident through his substantial patent portfolio and collaborative efforts. His contributions have the potential to transform treatment methodologies for cognitive disorders, making him a significant figure in the realm of medical inventions.

This text is generated by artificial intelligence and may not be accurate.